Percutaneous Sclerotherapy With Bleomycin Effective, Tolerable

This article originally appeared here.
Share this content:
Percutaneous Sclerotherapy With Bleomycin Effective, Tolerable
Percutaneous Sclerotherapy With Bleomycin Effective, Tolerable

FRIDAY, Sept. 22, 2017 (HealthDay News) -- Percutaneous bleomycin injections are effective and tolerable for the treatment of vascular malformations, according to a study published online Sept. 4 in the International Journal of Dermatology.

Hyun-Joo Lee, M.D., from the Pusan National University in Busan, South Korea, and colleagues evaluated the therapeutic efficacy and safety of percutaneous sclerotherapy using bleomycin for the treatment of vascular malformations in 30 patients. A mean of 3.2 treatment sessions were conducted over an average of three months.

The researchers found that significant improvement was observed in 90.0 percent of all lesions. There was significant improvement in all lesions of capillary malformation with nodular change and lymphatic malformation, as well as in 82.4 percent of lesions of venous malformation. Side effects, including pain and headache (rated as tolerable), occurred within 24 hours in seven patients (23.3 percent).

"Percutaneous sclerotherapy using bleomycin is effective and tolerable in the treatment of vascular malformation through a percutaneous approach," the authors write. "Therefore, it could be applied usefully for vascular malformations by dermatologists."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Doctors Urged to Speak With Patients About Firearms

Doctors Urged to Speak With Patients About Firearms

Making a public commitment is encouraged as a positive action that physicians can take

Machine Learning Model Predicts Risk of Upgrade to Breast CA

Machine Learning Model Predicts Risk of Upgrade to ...

Model can predict risk of upgrade of high-risk breast lesions to cancer using traditional, text features

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Glycemic Control Up With Oral Semaglutide in Type ...

Phase 3 studies next to assess longer-term/clinical outcomes, safety

is free, fast, and customized just for you!

Already a member?

Sign In Now »